Eli Lilly piles on weight loss drug suits to ward off revenue squeeze
Lawsuits against pharmacies in seven states aim to protect its flagship Mounjaro and Zepbound medications | Growing competition and patent expiration increase urgency for Lilly | New Jersey and Delaware stores accused of selling unapproved tirzepatide-based products.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
25 June 2024 US drugmaker files six lawsuits over compounded tirzepatide products | At least five deaths associated with ‘generic’ Mounjaro, according to complaint | Fears over drug's 'unapproved' use for cosmetic weight loss.
11 April 2024 Diabetes drug is known for its off-label use as a weight-loss aid | Judge censures pharma giant for using state law instead of federal law in complaint | Development follows a wave of litigation involving Mounjaro.